Antibody Humanization

Home ServicesAntibody Design & Engineering (AI)Antibody Humanization

Overview

Humanisation reduces the immunogenicity risk of a non-human antibody while trying not to lose the binding that made it worth developing. We assess the parental sequence against human germlines, select frameworks on structural as well as sequence grounds, design the graft with a reasoned set of back-mutations, and score each variant for humanness and predicted immunogenicity. Designs are delivered as a graded series so the trade-off between humanness and retained affinity can be measured rather than argued about.

Schematic: modelling covers the variable domains and CDR loops that determine binding, and developability liabilities are mapped across the whole sequence.

Key Advantages

Structure-Guided Back-Mutation

Vernier zone, canonical-class and interface residues are evaluated structurally, so back-mutations are proposed where they support the loop conformation rather than by sequence rule alone.

Graded Variant Series

Conservative through aggressive designs are delivered together, letting a small expression panel establish where affinity is lost instead of betting on a single construct.

Immunogenicity Assessed Two Ways

Germline content scoring and MHC class II binding prediction are used together, since each captures a different aspect of the clinical immunogenicity risk.

Liabilities Removed In The Same Pass

Developability motifs present in the parental sequence are addressed during humanisation, avoiding a second engineering cycle later.

Where This Service Is Used

Humanising a murine antibody derived from hybridoma work

Humanising a camelid VHH framework for therapeutic development

Improving the humanness score of an existing humanised antibody

Assessing the immunogenicity risk of a candidate before committing to development

Recovering affinity in a humanised construct that lost potency relative to the parent

Methods and Techniques Applied

Germline assignment, CDR definition and identification of the structurally critical framework positions

Variable domain structure modelling of the parental antibody, with the antigen complex where available

Human framework selection balancing sequence identity, canonical class compatibility and germline frequency

CDR grafting with structural evaluation of the graft junctions and supporting loops

Back-mutation design informed by Vernier zone, interface and canonical-structure analysis

Humanness scoring, MHC class II epitope prediction and developability liability screening

What We Need From You

Parental VH and VL sequences with the species of origin

Antigen information and any structural or epitope mapping data

Measured affinity and stability data for the parent, used as the benchmark

The intended clinical context, which determines how much immunogenicity risk is acceptable

What You Receive

Graded series of humanised sequences from conservative to fully germline-matched

Humanness scores and predicted immunogenicity assessment per variant

Structural models showing the graft and the rationale for each back-mutation

Developability liability report for the designed sequences

Recommended expression and testing order for the panel

What We Compute and Report

Germline content and humanness score per designed variant

Predicted T-cell epitope content across the sequence

Structural assessment of each graft junction and supporting framework position

Predicted stability and binding consequence for every back-mutation considered

Developability liability map for the humanised sequences

Interpretation and Limitations

Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, the structural evidence available and the applicability domain of the selected methods. Scores used for ranking are comparative devices and should not be read as measured quantities. All deliverables are for research use only and are not intended for diagnostic or therapeutic use.

Specifications

Item	Specification	Notes
Variants delivered	6–20 designs	Spanning the humanness-versus-affinity trade-off
Typical turnaround	2–4 weeks	Complex modelling adds time where required
Scoring	Germline content + MHC II	Both reported per variant
Output	Sequences, models, report	With back-mutation rationale per position

Service Workflow

Step 01

Scientific Consultation

We discuss the objective, the decision it supports and the data you hold. Nothing is quoted before we understand what the result has to answer.

Step 02

Feasibility Review

We check that the data, target class and available structural evidence can support the proposed approach, and say plainly where they cannot.

Step 03

Technical Proposal

Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.

Step 04

Computation and QC

The analysis runs on pinned tool versions in a containerised environment, with quality checkpoints and method comparison where that is informative.

Step 05

Report and Follow-Up

You receive the ranked results, the documented methods, the limitations and a proposed validation plan, plus support in interpreting them.

Is This the Right Service for You?

Choose this service when

A murine or camelid antibody is heading toward therapeutic development

Immunogenicity risk has to be documented for an internal or partner review

A previous humanisation attempt lost too much affinity

Consider another service when

The sequence is already human and needs affinity work

CDR Affinity Maturation

The format itself is changing as well

Bispecific & Multispecific Antibody Design

What Goes Wrong, and How We Handle It

The failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.

Canonical class compatibility and Vernier zone identity drive selection, and a slightly less identical framework is often the better choice.

Case Studies

The situation

A murine antibody needed humanising with as little affinity loss as possible and limited expression capacity.

What the work involved

Frameworks were shortlisted on canonical compatibility, back-mutation candidates were ranked structurally, and twelve variants were designed spanning conservative through fully germline-matched.

What came back

The panel identified the point at which affinity dropped sharply — between two specific back-mutations — allowing the most human variant on the acceptable side to be chosen with measured evidence.

Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.

Questions We Are Asked Before Scoping

Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.

Get in Touch
about Antibody Humanization

Tell us about the target, the data you hold and the decision the result needs to support. A scientist reviews every enquiry and replies within one business day.

Feasibility reviewed before any scope or price is fixed

Methods, parameters, confidence and limitations in every report

Confidentiality agreement available before data is shared